China (Mainland)
Premiumsupplier
99% Purity CAS 1256580-46-7 Alectinib Powder Anti-Tumor Alectinib Powder Raw Material Alectinib CAS NO.1256580-46-7
- Min.Order: 1 Gram
- Payment Terms: L/C,T/T,
- Product Details
Keywords
- 1256580-46-7
- Alectinib
- C30H34N4O2
Quick Details
- ProName: 99% Purity CAS 1256580-46-7 Alectinib ...
- CasNo: 1256580-46-7
- Molecular Formula: C30H34N4O2
- Appearance: white powder
- Application: Medicinal Chemistry
- DeliveryTime: as customers request
- PackAge: 1kg/foil bag;25kg/drum
- Port: any port in China
- ProductionCapacity: 100 Metric Ton/Month
- Purity: >99%
- Storage: Cool Dry Place
- Transportation: by sea or by air
- LimitNum: 1 Gram
Superiority
| 1)Quick Response Within 12 hours; |
| 2)Quality Guarantee: All products are strictly tested by our QC, confirmed by QA and approved by third party lab in China, USA, Canada, Germany, UK, Italy, France etc. |
| 3) OEM/ODM Available; |
| 4) Reasonable & Competitive Price; |
| 5) Fast Delivery: Samples from stock; bulk products within 7 days; |
| 6) Professional Documents for Your Clearance; |
| 7) Economic Freight Save Your Cost; |
| 8) All your money be refund immediately if quality issue happens. |
Details
Product information:
| Product Name | Alectinib |
| Appearance | White Powder |
| CAS No. | 1256580-46-7 |
| MF | C30H34N4O2 |
Alectinib is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells.
Alectinib is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been cl inically evaluated for the treatment of patients with ALK-driven tumors.
Alectinib is a second gene